Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Timing of Phase III for Panc

<< Previous

Bullboard Posts

Next >>

Comment by Hcallahan44on Nov 15, 2022 4:04pm

125 Views

Post# 35101159

RE:RE:RE:Timing of Phase III for Panc

Thanks Quentin...but what of KSW's point....the BPs are will run the Phase III after an acquisition...i have a biotech savvy friend who says that wont happen...the BPs will hold off and let us do the work....but if KSW is right....this wont be an issue. The market seems to be saying you are correct....if an acquisition was anywhere near....the stock would be jumping on heavy volume....

<< Previous

Bullboard Posts

Next >>

Victoria Gold: No cyanide detected downstream since mine incident